News & Updates

Show Multimedia Only

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

11 Dec 2025 by

A 70-year-old male was diagnosed with prostate cancer (PC) after presenting with increased urinary frequency and an elevated prostate-specific antigen (PSA) level of 71 ng/mL in October 2022. (Figure) MRI revealed a 3 cm left prostatic lesion without pelvic lymph node involvement or bone metastases, with possible extraprostatic extension and seminal vesicle invasion. Transperineal ultrasound-guided prostate biopsy confirmed prostatic adenocarcinoma in 8 out of 12 cores, with a Gleason score of 4 + 3.

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

11 Dec 2025

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

11 Dec 2025 by

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and historically poor outcomes. Prior to the emergence of antibody–drug conjugates (ADCs), palliative sequential single-agent chemotherapy was the mainstay of treatment for metastatic TNBC (mTNBC), offering limited response and survival. In an interview with MIMS Oncology, Dr Rodrigo Sánchez-Bayona from the Universitary Hospital 12 de Octubre, Madrid, Spain, discussed how Trop-2–targeted ADCs have changed the treatment landscape of mTNBC and predicted their future role in the changing treatment paradigm. He highlighted data on sacituzumab govitecan (SG), an ADC that has demonstrated efficacy regardless of Trop-2 expression status or presence of biomarkers while maintaining quality of life (QoL), and shared a patient case with rapidly progressing mTNBC effectively treated with SG.

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

11 Dec 2025

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

09 Dec 2025 by

Immune checkpoint inhibitors have substantially improved prognosis of patients with metastatic colorectal cancer (mCRC) characterized by microsatellite instability-high (MSI-H) status or mismatch repair deficiency (dMMR). At an industry-sponsored meeting organized by the Hong Kong Society of Digestive Oncology, Professor Heinz-Josef Lenz of the USC Norris Comprehensive Cancer Center in Los Angeles, California, US, discussed updated results of the phase III CheckMate 8HW trial, which support the paradigm shift in favour of first-line dual immunotherapy (IO) with nivolumab plus ipilimumab vs monotherapy and chemotherapy for patients with MSI-H/dMMR mCRC.

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

09 Dec 2025

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

28 Nov 2025 by

A 37-year-old female non-smoker was diagnosed in 2023 with stage IV non-small-cell lung cancer (NSCLC) harbouring EGFR exon 21 L858R mutation. Lymph node (LN), lung and bone metastases were present, and her Eastern Cooperative Oncology Group (ECOG) performance status was 0. Initially, the patient’s response to standard-of-care first-line osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), was good.¹ A PET scan after 6–8 months showed that the metastases had shrunk in response to treatment. However, oligoprogression was also observed at the primary lung tumour site, which was treated with radiotherapy.

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

28 Nov 2025

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

20 Nov 2025 by

A 69-year-old female diagnosed with localized stage T1b cholangiocarcinoma underwent an extended left hepatectomy with focally involved resection margins in April 2020. Adjuvant therapy was omitted due to prolonged postoperative intra-abdominal sepsis. She remained disease-free until December 2021, when a follow-up CT scan revealed a suspicious 6 mm lesion in liver segments 7/8. A subsequent CT scan in August 2022 showed interval enlargement of the lesion, confirming liver metastasis.

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

20 Nov 2025

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

20 Nov 2025 by

When treating hormone receptor–positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC), it is important to target the oestrogen receptor (ER) pathway for as long as the disease remains endocrine-sensitive. In an interview with MIMS Oncology, Dr Shaheenah Dawood, Head of the Oncology Clinical Trials Programme and Director of Oncology Services at Mediclinic City Hospital, Dubai, United Arab Emirates, described how co-targeting both the PI3K/AKT/mTOR and ER pathways with capivasertib and fulvestrant optimizes endocrine therapy (ET) to benefit patients with PIK3CA/AKT1/PTEN-altered HR+/HER2- mBC.

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

20 Nov 2025

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

15 Nov 2025 by

Pathological complete response (pCR) to earlier therapy is one of the key prognostic factors in patients with HER2-positive (HER2+) breast cancer (BC), which can help inform subsequent treatment decisions. In an interview with MIMS Oncology, Dr Joyce Lee, Specialist in Oncology in private practice in Hong Kong, discusses pCR and factors associated with disease recurrence, as well as data supporting the use of neratinib, an irreversible, small-molecule pan-HER tyrosine kinase inhibitor (TKI), as extended adjuvant therapy in hormone receptor– positive (HR+)/HER2+ BC.

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

15 Nov 2025

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

14 Nov 2025 by

Lung cancer remains the most common cancer and a leading cause of cancer-related mortality, with improved but still suboptimal survival outcomes despite advances in treatment. At a recent symposium chaired by Dr Shi-Feng Nyaw, Specialist in Clinical Oncology, Hong Kong, Professor Tianqing Chu, Consultant at the Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China, highlighted how tislelizumab, a novel immunotherapy agent, differs from other anti–programmed death receptor 1 (PD-1) therapies. She presented efficacy and safety data for tislelizumab in both squamous and non-squamous non-small-cell lung cancer (NSCLC) from RATIONALE-307/304 and her routine clinical practice. Additionally, Professor Victor Lee, Clinical Professor at the Department of Clinical Oncology, The University of Hong Kong, shared real-world cases illustrating the clinical benefits of tislelizumab in NSCLC patients.

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

14 Nov 2025

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

29 Oct 2025

The phase I/II TRIDENT-1 trial demonstrates high ORR and durable activity of repotrectinib, a next-generation TKI, in TKI-naïve and -pretreated ROS1+ or NTRK1–3+ locally advanced or metastatic NSCLC, including patients from Asia.

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

29 Oct 2025

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

25 Oct 2025 by

A 70-year-old woman with stage 2A triple-negative breast cancer (TNBC; pT1cN1a) and excellent performance status (PS) underwent left total mastectomy followed by adjuvant chemotherapy. Genetic testing revealed no germline BRCA1/2 mutations. Three years later, she developed neck and upper limb swelling. Left neck biopsy confirmed triple-negative metastatic disease with PD-L1 combined positive score (CPS) >75. She received weekly paclitaxel and pembrolizumab, achieving a good response. After 21 cycles (approximately 1.5 years), she developed a sternal nodule, which was surgically excised; pathology indicated triple-negative grade 3 invasive carcinoma with extensive lymphovascular invasion. Molecular testing showed no targetable mutations.

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

25 Oct 2025

News & Updates

Showing Oncology articles

Showing

Specialty:

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives